3-methyl-5-(1-methylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-phenylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-propan-2-ylimidazol-2-yl)pyrazol-1-ide;tris(platinum(2+));tris(2-[5-(trifluoromethyl)-1,4-diaza-2-azanidacyclopenta-3,5-dien-3-yl]pyrimidine)
C52H42F9N27Pt3 — CID 159675589
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-methyl-5-(1-methylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-phenylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-propan-2-ylimidazol-2-yl)pyrazol-1-ide;tris(platinum(2+));tris(2-[5-(trifluoromethyl)-1,4-diaza-2-azanidacyclopenta-3,5-dien-3-yl]pyrimidine)
3-methyl-5-(1-methylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-phenylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-propan-2-ylimidazol-2-yl)pyrazol-1-ide;tris(platinum(2+));tris(2-[5-(trifluoromethyl)-1,4-diaza-2-azanidacyclopenta-3,5-dien-3-yl]pyrimidine) (PubChem CID 159675589) has the molecular formula C52H42F9N27Pt3 and a molecular weight of 1801.31 g/mol. Its IUPAC name is 3-methyl-5-(1-methylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-phenylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-propan-2-ylimidazol-2-yl)pyrazol-1-ide;tris(platinum(2+));tris(2-[5-(trifluoromethyl)-1,4-diaza-2-azanidacyclopenta-3,5-dien-3-yl]pyrimidine).
Molecular Properties
| Compound Name | 3-methyl-5-(1-methylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-phenylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-propan-2-ylimidazol-2-yl)pyrazol-1-ide;tris(platinum(2+));tris(2-[5-(trifluoromethyl)-1,4-diaza-2-azanidacyclopenta-3,5-dien-3-yl]pyrimidine) |
|---|---|
| PubChem CID | 159675589 |
| Molecular Formula | C52H42F9N27Pt3 |
| Molecular Weight | 1801.31 g/mol |
| Exact Mass | 1800.29 |
| IUPAC Name | 3-methyl-5-(1-methylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-phenylimidazol-2-yl)pyrazol-1-ide;3-methyl-5-(1-propan-2-ylimidazol-2-yl)pyrazol-1-ide;tris(platinum(2+));tris(2-[5-(trifluoromethyl)-1,4-diaza-2-azanidacyclopenta-3,5-dien-3-yl]pyrimidine) |
| SMILES | Cc1cc(-c2nccn2-c2ccccc2)[n-]n1.Cc1cc(-c2nccn2C(C)C)[n-]n1.Cc1cc(-c2nccn2C)[n-]n1.FC(F)(F)c1n[n-]c(-c2ncccn2)n1.FC(F)(F)c1n[n-]c(-c2ncccn2)n1.FC(F)(F)c1n[n-]c(-c2ncccn2)n1.[Pt+2].[Pt+2].[Pt+2] |
| InChI | InChI=1S/C13H11N4.C10H13N4.C8H9N4.3C7H3F3N5.3Pt/c1-10-9-12(16-15-10)13-14-7-8-17(13)11-5-3-2-4-6-11;1-7(2)14-5-4-11-10(14)9-6-8(3)12-13-9;1-6-5-7(11-10-6)8-9-3-4-12(8)2;3*8-7(9,10)6-13-5(14-15-6)4-11-2-1-3-12-4;;;/h2-9H,1H3;4-7H,1-3H3;3-5H,1-2H3;3*1-3H;;;/q6*-1;3*+2 |
| InChIKey | MUOCLATWWIVDDW-UHFFFAOYSA-N |
| XLogP | 7.46 |
| TPSA | 331.41 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 21 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 91 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1801.31 |
| LogP ≤ 5 | 7.46 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 21 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 159675589 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.